XML 55 R43.htm IDEA: XBRL DOCUMENT v3.25.2

Liabilities Related to Business Combinations and to Non-Controlling Interests (Tables)

6 Months Ended

Jun. 30, 2025

Disclosure of contingent liabilities in business combination [abstract]

Summary of Movements in Liabilities Related to Business Combinations and to Non-Controlling Interests

Movements in liabilities related to business combinations and to non-controlling interests in the first half of 2025 are shown below:

(€ million)												MSD contingent consideration (European Vaccines business)			Shire contingent consideration arising from acquisition of Translate Bio						Other			Total (a)
Balance at January 1, 2025												72			568						1			641
Payments made												(72)			—						—			(72)
Fair value remeasurements through profit or loss: (gain)/loss (including unwinding of discount) (b)												1			71						—			72
Currency translation differences												(1)			(76)						—			(77)
Balance at June 30, 2025												—			563						1			564
Of which:
•Current portion																								—
•Non-current portion																								564

(a)As of January 1, 2025, this comprised a non-current portion of €569 million and a current portion of €72 million.

(b    Amounts mainly reported within the income statement line item “Fair value remeasurement of contingent consideration”.

X

- References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfContingentLiabilitiesInBusinessCombinationAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of changes in liabilities related to business combinations and to non-controlling interests.

+ References

No definition available.

+ Details

Name:	sny_DisclosureOfChangesInLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsTableTextBlock
Namespace Prefix:	sny_
Data Type:	dtr-types1:textBlockItemType
Balance Type:	na
Period Type:	duration